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Psoralen and ultraviolet A (PUVA) is useful in treating various hand and foot skin 
diseases.1 Most cases of psoriasis respond well to phototherapy or PUVA. However, for 
some diseases, such as palmoplantar pustular psoriasis, PUVA is not always sufficient to 
produce therapeutic effect. If PUVA fails, it is sometimes necessary to progress to other 
treatments such as Grenz ray therapy (where available),2 systemic retinoid or systemic 
immunosuppression. Could “PUVA1” (psoralen combined with ultraviolet A1 long 
wavelength ultraviolet A [UVA]) work in cases where conventional PUVA (psoralen plus 
broadband UVA) has been inadequate? 
Previous in-vitro and in-vivo work has indicated that longer UVA wavelengths can 
activate Psoralen and induce erythema3,4. Combine this with the fact that longer UV 
wavelengths penetrate deeper into tissue (and this is probably why UVA1 monotherapy 
might work in palmoplantar pustulosis5), and a potential result is that psoralen plus a 
UVA1 source might be more effective than the standard broadband UVA source in 
treating conditions that affect sites with a thick epidermis, such as palms and soles of A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
feet. 
We wanted to determine if PUVA1 might be a useful treatment, before deciding whether 
or not a pilot clinical study would be appropriate.
Monte Carlo radiative transfer (MCRT) methods use localised scattering and absorption 
probabilities to describe the path of photon packets through a medium, and are ideally 
suited to modelling a complex structure such as the upper layers of the skin6. These 
computationally intensive methods rely on repeated random sampling to form predictive 
models of radiation transport through a scattering medium, such as the skin7. MCRT 
methods are widely used and rely upon published optical properties of the tissue. Using a 
modified version of a previously published 5 layered MCRT skin model,8 irradiation by 
several phototherapy light sources (metal halide UVA1, fluorescent lamp UVA1, 
broadband UVA (“PUVA tubes”) and narrowband ultraviolet B (a standard phototherapy) 
was simulated. Four simulations were performed, one for each light source, and each 
simulation was run with 100 million photon packets, to achieve statistically significant 
results. The total fluence, at depth, achieved by each light source is recovered. The four 
simulations were repeated for psoriatic skin, achieved by thickening the modelled stratum 
corneum (keratin layer of epidermis) by a factor of two.  
The results of our simulations quantify the depth penetration advantage achieved by 
UVA1 (both fluorescent and metal halide lamps) over that achieved by broadband UVA 
and narrowband UVB. The advantage is smaller at 50% of incident fluence, but larger 
when considering the depth of 10% of the fluence (Table 1).  In addition, we found that 
psoriatic tissue greatly reduced the depth achieved by all lamps - the stratum corneum 
strongly scatters and absorbs UV radiation, so thickening of this, by psoriatic scales, will 
greatly reduce the UV radiation reaching deeper layers of the skin. Given that the 
absorption spectrum of psoralen overlaps with the emission spectrum of UVA1 and the 
clinical evidence demonstrating the efficiency of longer wavelengths4 it may be possible 
to combine the two and achieve greater depth effect than with standard PUVA therapy. 
However as longer, less psoralen-effective wavelengths, reach the deeper depths, it is 
still not clear whether there will be enough activation of psoralen at deeper depths. A
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Following the example of Al-Ismail et al.4, at depth of 250 µm in healthy tissue, the Metal 
halide UVA1 source has a PUVA effective ratio of 0.207. 
In conclusion, our results suggest that UVA1 radiation may be suitable for combination 
with psoralen in cases where deeper depth penetration is required than with conventional 
PUVA. However, this is dependent on how the penetrating UV radiation actually interacts 
with psoralen treated cells at depth within the skin and requires further investigation. We 
are planning a pilot study of PUVA1 in palmoplantar pustulosis.
Table 1. The results in Table 1 present the depth, measured from the surface of the skin, 
that 50% and 10% of the total integrated incident radiation has reached. In addition, for 
the Metal Halide UVA1 lamp, we present the depths reached by 50% and 10% of the 
radiation in the wavelength bands comprising the lamp’s output. 
Lamp Healthy Skin Psoriatic Skin 
Depth Of 
50% 
Incident
Depth Of 
10% Incident
Depth Of 
50% Incident
Depth Of 
10% Incident
Broadband UVA 
(PUVA) 
37 µm 215 µm 16 µm 65 µm
Narrowband UVB 17 µm 124 µm 14 µm 41 µm
Fluorescent UVA1 45 µm 254 µm 18 µm 83 µm
Metal Halide UVA1 46 µm 251 µm 19 µm 85 µm
340nm-350nm 33 µm 192 µm 16 µm 57 µm
350nm-360nm 39 µm 220 µm 17 µm 66 µm
360nm-370nm 43 µm 247 µm 18 µm 75 µm
370nm-380nm 47 µm 264 µm 19 µm 88 µm
380nm-390nm 49 µm 262 µm 20 µm 101µmA
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390nm-400nm 51 µm 257 µm 20 µm 102 µm
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